Hereditary Transthyretin-mediated Amyloid Polyneuropathy
📧 Sign up to get email alerts when something new happens for Hereditary Transthyretin-mediated Amyloid Polyneuropathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy [Phase 3]
A Phase 3 long-term safety and efficacy trial of Eplontersen for hereditary transthyretin-mediated amyloid polyneuropathy is ongoing and cur…
-
CLINICAL_TRIALS trial_result · 2024-12-10Clinical Trial Update: NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy [Phase 3]
Phase 3 NEURO-TTRansform study evaluating the efficacy and safety of Eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy…